Real cryosleep, in the sense of a healthy person pausing biological time for decades and waking intact, remains firmly in science fiction. The honest current answer is that we can already slow biology dramatically in narrow, high-risk settings, and we can preserve cells and small tissues at cryogenic temperatures, but we cannot reversibly suspend a whole human body. Everything achieved so far is either deep hypothermia measured in hours or preservation that ends in death or irreversible injury.
The gap is not one problem but several stacked ones: ice damage, oxygen debt, metabolic poisoning, and the absence of any proven way to restart a human brain after prolonged cold storage. This explainer separates what exists today from what would have to be invented, with mechanisms, numbers, and explicit limits on what the evidence supports.
The core mechanism: cold slows chemistry but does not stop it
Biological rates fall with temperature because molecular collisions lose energy. In broad terms, cooling tissue by roughly 10 degrees Celsius can cut metabolic rate by about half in many systems, a relationship often summarized as the Q10 effect. That is why cold works: a chilled brain needs far less oxygen and burns far less fuel per minute.
But two problems arrive with the cold. First, below the freezing point of body fluids, ice crystals form and mechanically shred cell membranes and blood vessels. Second, even before freezing, ion pumps that depend on energy fail, so calcium and sodium leak across membranes and trigger cell death programs. The body's own chemistry becomes the executioner.
The workaround biologists use for cells is to add cryoprotectants, chemicals that replace water and suppress ice formation, then cool slowly with controlled-rate freezing. For a single cell this can work. For an organ or a whole body, the cryoprotectant must penetrate every tissue fast enough to prevent freezing damage but not so fast or concentrated that it becomes chemically toxic. That tradeoff is the central unsolved engineering problem. In plain terms, we can protect a droplet of cells far more easily than a liter of structured tissue.
Quantified context: what is actually achievable now
Clinical deep hypothermia is real and routine in cardiac and aortic surgery. Patients are cooled to roughly 18 to 20 degrees Celsius, circulation is stopped, and surgeons operate on a still, bloodless field for a bounded window. The safe limit for circulatory arrest at those temperatures is generally cited as around 20 to 40 minutes before neurological injury risk rises sharply. This is not sleep. It is controlled, temporary, and heavily monitored, and the patient is warmed and resuscitated within the same operation.
Organ preservation shows the frontier more clearly. Static cold storage keeps a kidney viable for roughly 24 hours and a heart for only about 4 to 6 hours. Machine perfusion extends some of these windows. None of this approaches years.
On the freezing side, the well-documented cases are cells and thin tissues: sperm, embryos, and eggs stored in liquid nitrogen at about minus 196 degrees Celsius for decades with high survival after thaw. Vitrification, which turns tissue into a glass-like state without ice, has allowed successful preservation and transplantation of ovarian tissue and, experimentally, whole ovaries in animals. The step from a millimeter-scale tissue strip to a 70-kilogram human with a 1.4-kilogram brain is not incremental.
A comparison of the options on the table
| Approach | Temperature | Duration achieved | Reversible in humans | Main barrier |
|---|---|---|---|---|
| Therapeutic hypothermia | 32–36 C | Hours to days | Yes, routinely | Infection, clotting, heart rhythm risk |
| Deep hypothermic circulatory arrest | 18–20 C | 20–40 min safe window | Yes, in surgery | Neurologic injury beyond window |
| Static cold organ storage | 4 C | 4–24 hours | Yes, for transplant | Tissue decay, no long-term pause |
| Vitrified cells and thin tissue | About −196 C | Decades | Yes, for fertility tissue | Scale, cryoprotectant penetration |
| Whole-body cryonics | About −196 C | Years of storage | No, unproven | Ice and toxicity damage, no revival protocol |
The table makes the pattern visible. Every reversible case is either short-duration cooling or small-scale freezing. The long-duration, whole-body cases are storage without demonstrated return.
Edge cases and the counterintuitive detail
The most counterintuitive finding is that freezing a whole organ is often harder than freezing single cells precisely because the organ is organized. A cell can be loaded with cryoprotectant from all sides at once. A kidney or brain has a vascular tree, dense lipid-rich myelin, and barriers that slow chemical penetration. Cooling too fast cracks tissue; cooling too slowly lets the cryoprotectant concentrate unevenly and dehydrate compartments. There is a narrow window between those failure modes, and for large organs it is very narrow.
A second edge case is the distinction between preservation and resuscitation. Cryonics organizations store bodies or brains at cryogenic temperature after death, betting on future repair. As of today there is no published evidence of a mammal revived after whole-body cryopreservation, and no protocol for repairing the freezing and cryoprotectant damage even in principle. The professional caveat is blunt: storage is not the hard part. Reversible recovery of a structured human brain is the hard part, and nobody has demonstrated it.
There is also a regulatory edge. The FDA has not approved any procedure or product marketed as human cryopreservation for revival, and cryonics providers operate outside standard medical approval pathways. That is a status statement, not a verdict on the underlying physics.
Misconceptions worth correcting
The most common error is conflating three different things: therapeutic cooling, organ preservation, and cryonics. They share the word cold and almost nothing else. Therapeutic cooling is proven medicine. Organ preservation is proven for transplant windows. Cryonics is an unproven speculative service.
A second misconception is that suspended animation means zero metabolism. At cryogenic temperatures chemistry is extremely slow but not truly stopped, and at hypothermic temperatures it is merely reduced. The difference matters because a slowed metabolism still consumes fuel and accumulates waste, which is why even deep hypothermia has a time limit.
A third is that the brain is simply another organ to chill. Brain tissue is uniquely vulnerable to oxygen debt and to the calcium-driven cascade that follows energy failure. The 20-to-40-minute circulatory arrest window exists because of that vulnerability, not because of equipment limits. Finally, people assume a breakthrough in one area transfers to the others. A better cryoprotectant for embryos does not automatically scale to a brain, because the barrier is penetration depth and tissue architecture.
Practical actions and thresholds that matter
If you are trying to reason about cryosleep claims, apply concrete tests rather than vibes. The following checklist reflects what the evidence actually supports:
Ask for a demonstrated reversible recovery of a whole mammal after cryopreservation, not a cell or tissue result. Check the temperature and duration claimed: 4 C for hours and −196 C for years are different claims with different evidence. Require a peer-reviewed resuscitation protocol, not a storage contract. Distinguish therapeutic cooling in surgery (18–20 C, 20–40 min) from speculative whole-body suspension. Treat marketing language about "waking up in the future" as unproven until a brain-level recovery is published. Verify any medical claim against an authoritative body such as the FDA rather than a provider's website.
For clinical decisions, the actionable threshold is simpler: deep hypothermia and organ cold storage are established and governed by surgical and transplant protocols, and those decisions belong to clinicians. Whole-body cryopreservation has no established clinical threshold because it has no demonstrated reversal.
Where the evidence stops and the timeline begins
The timeline below separates what is established from what is speculative, so the difference is explicit rather than blurred by optimism.
| Era | Milestone | Status |
|---|---|---|
| 1950s | Deep hypothermia used in cardiac surgery | Established |
| 1960s–70s | Cryoprotectants and slow-freeze cell banking | Established |
| 1980s–2000s | Vitrification improves egg and embryo survival | Established for cells and thin tissue |
| 2000s–present | Machine perfusion extends organ windows | Established for transplant, hours to about a day |
| Present | Whole-organ vitrification and rewarming | Experimental, not routine |
| Present | Whole-body cryonics with revival | No demonstrated success |
| Future | Reversible whole-brain cryopreservation | Speculative, no timeline supported by evidence |
The last row is the crux. There is no credible published date for reversible human cryosleep, and any specific year offered is invention rather than forecast. What can be said is directional: the field is advancing on organs and tissues, and the hardest unsolved problems are cryoprotectant penetration at scale, ice-free rewarming of large tissue, and repair of the injury that cooling itself causes.
So how close are we to real cryosleep? For cells and thin tissues, we are already there. For organs, we are at hours, not years. For a whole human paused and revived, we are not close in any evidence-based sense. The mechanism is understood well enough to know exactly which barriers stand in the way, and that clarity is more useful than a hopeful number.